Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Kalkine 0
countryflagAU

Neurizon Therapeutics Limited

Healthcare AU NUZ

0.16AUD
0.005(3.23%)

Last update at 2025-07-02T05:32:00Z

Day Range

0.150.17
LowHigh

52 Week Range

0.100.24
LowHigh

Fundamentals

  • Previous Close 0.15
  • Market Cap68.92M
  • Volume391176
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-11.87481M
  • Revenue TTM1.52M
  • Revenue Per Share TTM0.003
  • Gross Profit TTM 1.52M
  • Diluted EPS TTM-0.03

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Income before tax -8.89992M -6.21156M -1.70821M -1.33731M
Minority interest - - - -
Net income -7.67315M -6.21156M -1.70821M -1.33731M
Selling general administrative 2.81M 4.30M 4.74M 3.85M
Selling and marketing expenses - - - -
Gross profit - 2.04M 3.07M 1.92M
Reconciled depreciation 0.00164M 0.33M 0.31M 0.30M
Ebit - - - -
Ebitda - - - -
Depreciation and amortization - - - -
Non operating income net other - - - -
Operating income -6.65863M -3.70061M -2.74913M -2.79135M
Other operating expenses - - - -
Interest expense - 0.08M 0.09M 0.08M
Tax provision 0.00000M 0.00000M 0.00000M 0.00000M
Interest income 0.02M 0.08M 0.00054M 0.01M
Net interest income 0.02M -0.00084M -0.08797M -0.06427M
Extraordinary items - - - -
Non recurring - - - -
Other items - - - -
Income tax expense - - - -
Total revenue - 2.82M 3.38M 2.14M
Total operating expenses - - - -
Cost of revenue - 0.79M 0.31M 0.23M
Total other income expense net -2.26576M -2.51012M 1.13M 1.52M
Discontinued operations - - - -
Net income from continuing ops -8.89992M -6.21156M -1.70821M -1.33731M
Net income applicable to common shares - - - -
Preferred stock and other adjustments - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Total assets 11.12M 6.13M 10.08M 10.95M
Intangible assets - 3.11M 3.11M 3.14M
Earning assets - - - -
Other current assets 1.14M 0.08M 0.02M 0.02M
Total liab 0.90M 2.24M 2.23M 2.07M
Total stockholder equity 10.23M 3.89M 7.84M 8.88M
Deferred long term liab - - - -
Other current liab 0.04M - - -
Common stock - - - -
Capital stock 69.94M 57.63M 55.34M 55.33M
Retained earnings -64.13204M -56.45889M -50.24733M -48.53912M
Other liab - - - -
Good will - - - -
Other assets - - - -
Cash 9.71M 2.71M 2.42M 3.02M
Cash and equivalents - - - -
Total current liabilities 0.90M 1.35M 1.17M 0.91M
Current deferred revenue - - - -
Net debt - - - -
Short term debt - - - -
Short long term debt - - 0.21M 0.04M
Short long term debt total - - - -
Other stockholder equity - - - -
Property plant equipment - - - -
Total current assets 11.12M 3.02M 3.73M 4.36M
Long term investments - - - -
Net tangible assets - - - -
Short term investments - - - -
Net receivables 0.02M 0.23M 0.19M 0.24M
Long term debt - - - -
Inventory - - 1.04M 1.01M
Accounts payable 0.83M 0.93M 0.60M 0.56M
Total permanent equity - - - -
Noncontrolling interest in consolidated entity - - - -
Temporary equity redeemable noncontrolling interests - - - -
Accumulated other comprehensive income - - - -
Additional paid in capital - - - -
Common stock total equity - - - -
Preferred stock total equity - - - -
Retained earnings total equity - - - -
Treasury stock - - - -
Accumulated amortization - - - -
Non currrent assets other - - - -
Deferred long term asset charges - - - -
Non current assets total 0.00000M 3.11M 6.35M 6.60M
Capital lease obligations - 1.05M 1.17M 1.24M
Long term debt total - - - -
Breakdown 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Type yearly yearly yearly yearly
Date 2024-06-30 2023-06-30 2022-06-30 2021-06-30
Investments -1.16523M -0.03493M -0.04338M -0.13804M
Change to liabilities - - - -
Total cashflows from investing activities - - - -
Net borrowings - - - -
Total cash from financing activities 13.34M 1.89M 0.77M 1.22M
Change to operating activities - - - -
Net income -7.67315M -6.21156M -1.70821M -1.33731M
Change in cash 7.01M 0.29M -0.60465M 0.14M
Begin period cash flow 2.71M 2.42M 3.02M 2.88M
End period cash flow 9.71M 2.71M 2.42M 3.02M
Total cash from operating activities - - - -
Issuance of capital stock 13.31M 2.24M 0.72M 1.54M
Depreciation - - - -
Other cashflows from investing activities - - - -
Dividends paid - - - -
Change to inventory - - - -
Change to account receivables - - - -
Sale purchase of stock - - - -
Other cashflows from financing activities - - - -
Change to netincome - - - -
Capital expenditures 0.00000M 0.03M 0.04M 0.14M
Change receivables - - - -
Cash flows other operating - - - -
Exchange rate changes - - - -
Cash and cash equivalents changes - - - -
Change in working capital - - - -
Stock based compensation - - - -
Other non cash items - - - -
Free cash flow -5.16857M -1.59911M -1.37564M -1.07600M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (AUD) Price (AUD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NUZ
Neurizon Therapeutics Limited		 0.005 3.23% 0.16 - - 45.47 6.20 8.72 -22.5865
CSL
CSL Ltd		 1.53 0.64% 239.77 28.55 32.05 7.64 4.03 5.80 18.01
TLX
Telix Pharmaceuticals Ltd		 0.68 2.83% 24.75 177.75 56.82 10.64 14.57 10.40 88.05
MSB
Mesoblast Ltd		 -0.165 8.97% 1.68 - 454.55 369.57 2.90 67.90 -9.8623
NEU
Neuren Pharmaceuticals Ltd		 -0.25 1.75% 14.00 12.99 78.12 8.25 4.61 7.03 8.53

Reports Covered

Stock Research & News

View All

Profile

Neurizon Therapeutics Limited, a clinical stage biotechnology company, develops therapeutics for neurodegenerative diseases in Switzerland, Australia, the United States, and internationally. The company develops drug discovery intellectual property for the treatment of various cancers and neurological diseases. Its lead candidate is Monepantel (MPL), a small molecule drug which is in Phase II clinical trials for the treatment of amyotrophic lateral sclerosis, as well as to treat other neurodegenerative diseases, such as Alzheimer's and Parkinson's disease. The company was formerly known as PharmAust Limited and changed its name to Neurizon Therapeutics Limited in October 2024. Neurizon Therapeutics Limited was incorporated in 2000 and is based in Melbourne, Australia.

Neurizon Therapeutics Limited

Suite 2, Melbourne, VIC, Australia, 3000

Key Executives

Name Title Year Born
Dr. Michael Thurn Ph.D. MD, CEO & Director NA
Mr. John Clark Chief Operating Officer NA
Dr. Nicky Wallis Chief Scientific Officer NA
Ms. Fiona Milner General Manager of Epichem Pty Ltd NA
Dr. Gary Pitt Head of Chemistry NA
Dr. James Rixson Head of Production NA
Dr. Herbert Brinkman Head of Manufacturing NA
Mr. Stefan Ross Company Secretary NA
Ms. Lidija Damjanovic Head of Marketing & Corporate Affairs NA
Dr. Chris Freitag M.D. Chief Medical Advisor 1967

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.